Nova Leap Health Corp.
Nova Leap Health Corp. (NLH.V) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
nlh.v · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Nova Leap Health Corp. (NLH.V) measures how much investors pay for each dollar of the company's trailing earnings. NLH.V's current PE ratio of 114.95x is calculated by dividing its stock price of $0.38 by its TTM earnings per share of $0.00. +449.2% elevated vs 5Y avg 20.9x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2016 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 3 fiscal years · Front-end computedMinQ1 · 25%20.4x
MedianQ3 · 75%30.5x
Max
At 114.95x, NLH.V's current P/E is higher than in 100% of its annual fiscal year readings over the past 3 years — historically elevated.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Care Facilities · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Nova Leap Health Corp.You NLH.V | $33M | 114.95x | — | $0.00 |
 Aurora Spine Corporation ASG.V | $17M | N/A | — | -$0.01 |
 BriaCell Therapeutics Corp. BCT.TO | $8M | N/A | — | -$62.95 |
 Rapid Dose Therapeutics Corp. DOSE.CN | $12M | N/A | — | -$0.04 |
 Gemina Laboratories Ltd. GLAB.CN | $5M | N/A | — | -$0.06 |
 Greenway Greenhouse Cannabis Corporation GWAY.CN | $21M | N/A | — | -$0.02 |
 Izotropic Corporation IZO.CN | $19M | N/A | — | -$0.05 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.00 | — | |
2024-12-31 FY2024 | 11.92x | $0.02 | — | |
2023-12-31 FY2023 | — | $-0.01 | — | |
2022-12-31 FY2022 | — | $-0.01 | — | |
2021-12-31 FY2021 | 20.38x | $0.02 | -33.2% | |
2020-12-31 FY2020 | 30.51x | $0.02 | — | |
2019-12-31 FY2019 | — | $-0.02 | — | |
2018-12-31 FY2018 | — | $-0.02 | — | |
2017-12-31 FY2017 | — | $-0.04 | — | |
2016-12-31 FY2016 | — | $-0.04 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Nova Leap Health Corp. (NLH.V) measures how much investors pay for each dollar of the company's trailing earnings. NLH.V's current PE ratio of 114.95x is calculated by dividing its stock price of $0.38 by its TTM earnings per share of $0.00.
Frequently asked questions
NLH.V pe ratio · 6 questionsNLH.V's current PE ratio is 114.95x as of 2026-06-08, based on a stock price of $0.38 and TTM EPS of $0.00. Data sourced from Financial Modeling Prep via NLH.V's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Nova Leap Health Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08